Pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that begins in the cells lining the ducts of the pancreas, the organ responsible for producing digestive enzymes and hormones like insulin. It is the most common form of pancreatic cancer, accounting for about 85-90% of all pancreatic cancer cases. Unlike some cancers that develop slowly, PDAC typically progresses aggressively and is often detected at advanced stages because early symptoms are often absent or vague. The disease involves malignant cells that originate in the epithelial cells of the pancreatic ducts and can spread to surrounding tissues and distant organs.

PDAC is central to oncology, gastroenterology, and surgical medicine, with researchers and clinicians worldwide dedicating significant effort to understanding and treating it. It matters profoundly because pancreatic cancer has one of the poorest survival rates among all cancers, with a five-year survival rate of only about 10% globally. The disease impacts hundreds of thousands of people annually, making it a major public health concern. Scientists study PDAC to understand how normal pancreatic cells transform into cancer cells and how the disease becomes so resistant to treatment.

PDAC develops through a series of genetic mutations that accumulate in pancreatic duct cells over time, much like a series of locks being broken one by one in a security system. Key genes involved include KRAS (which becomes hyperactive in most PDAC cases), TP53 (a tumor suppressor that fails), and others like BRCA1/BRCA2 and CDKN2A. As these mutations pile up, cells lose their ability to regulate growth and division, eventually forming tumors that invade surrounding tissue and spread to other organs. The pancreas's deep location in the abdomen and the tumor's aggressive nature make early detection extremely challenging.

PDAC research is critical for developing new diagnostic tools that can catch the disease earlier, when treatment options are more effective, and for creating novel therapies that overcome the tumor's notorious resistance to chemotherapy and radiation. Understanding the genetic and molecular basis of PDAC has led to precision medicine approaches and immunotherapies that offer hope for improving patient outcomes. The disease remains one of the most urgent challenges in cancer research, driving innovation in both basic science and clinical practice.